New drug combo aims to control aggressive blood disorder
NCT ID NCT03383575
Summary
This study is testing a targeted drug called enasidenib, sometimes combined with another drug (azacitidine), for people with a high-risk type of blood and bone marrow disorder called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if this approach is safe and can help control the disease by stopping the growth of abnormal cells. The trial will enroll about 63 participants who either haven't tried a certain type of therapy before or whose disease has come back after that therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH2 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44195, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
ACTIVE_NOT_RECRUITINGBaltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.